Tumor necrosis factor alpha antagonist drugs and leishmaniasis in Europe

Clinical Microbiology and Infection

Volumn 18, Issue 7, 2012, Pages 670-676

  Zanger, P ^a   Kotter I ^b   Kremsner, P G ^a   Gabrysch, S ^c  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Leishmaniasis; Opportunistic infections; Pharmacoepidemiology; Tumor necrosis factor alpha

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; DRUG SURVEILLANCE PROGRAM; EUROPE; HEALTH CARE PERSONNEL; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LEISHMANIASIS; MEDLINE; OPPORTUNISTIC INFECTION; PRESCRIPTION; PRIORITY JOURNAL; PUBLICATION; RISK;

EID: 84859598217     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2011.03674.x     Document Type: Article

References (43)

1. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38: 1261-1265.
2. Tubach F, Salmon D, Ravaud P et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective french research axed on tolerance of biotherapies registry. Arthritis Rheum 2009; 60: 1884-1894.
3. Romani-Costa V, Sanchez C, Moya F, Estany C. [Visceral leishmaniasis related to infliximab administration]. Enferm Infecc Microbiol Clin 2004; 22: 310.
4. Fabre S, Gibert C, Lechiche C, Dereure J, Jorgensen C, Sany J. Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with infliximab. Clin Exp Rheumatol 2005; 23: 891-892.
5. Bassetti M, Pizzorni C, Gradoni L, Del Bono V, Cutolo M, Viscoli C. Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with adalimumab. Rheumatology (Oxford) 2006; 45: 1446-1448.
6. Bagalas V, Kioumis I, Argyropoulou P, Patakas D. Visceral leishmaniasis infection in a patient with rheumatoid arthritis treated with etanercept. Clin Rheumatol 2007; 26: 1344-1345.
7. Tektonidou MG, Skopouli FN. Visceral leishmaniasis in a patient with psoriatic arthritis treated with infliximab: reactivation of a latent infection? Clin Rheumatol 2008; 27: 541-542.
8. Xynos ID, Tektonidou MG, Pikazis D, Sipsas NV. Leishmaniasis, autoimmune rheumatic disease, and anti-tumor necrosis factor therapy, europe. Emerg Infect Dis 2009; 15: 956-959.
9. Schneider P, Bouaziz JD, Foulet F, Duong TA, Allanore LV, Bagot M. [Multifocal cutaneous leishmaniasis due to Leishmania infantum under adalimumab therapy]. Ann Dermatol Venereol 2009; 136: 815-816.
10. Balta-Cruz S, Alsina-Glbert M, Mozos-Rocafort A et al. Pseudolymphomatoid cutaneous leishmaniasis in a patient treated with adalimumab for rheumatoid arthritis. Acta Derm Venereol 2009; 89: 432-433.
11. De Leonardis F, Govoni M, Lo Monaco A, Trotta F. Visceral leishmaniasis and anti-tnf-alpha therapy: case report and review of the literature. Clin Exp Rheumatol 2009; 27: 503-506.
12. Mueller MC, Fleischmann E, Grunke M, Schewe S, Bogner JR, Loscher T. Relapsing cutaneous leishmaniasis in a patient with ankylosing spondylitis treated with infliximab. Am J Trop Med Hyg 2009; 81: 52-54.
13. Garcia-Vidal C, Rodriguez-Fernandez S, Teijon S et al. Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention. Eur J Clin Microbiol Infect Dis 2009; 28: 331-337.
14. Kritikos K, Haritatos E, Tsigkos S et al. An atypical presentation of visceral leishmaniasis infection in a patient with rheumatoid arthritis treated with infliximab. J Clin Rheumatol 2010; 16: 38-39.
15. Hakimi S, Riviere S, Del Giudice P, Dereure J, Le Quellec A. Localized cutaneous leishmaniasis due to Leishmania infantum in a patient treated with infliximab. Dermatology 2010; 220: 63-65.
16. Moreno D, Martinez P, Berbegal J, Femenia M. [Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with adalimumab: a case description and literature review]. Enferm Infecc Microbiol Clin 2010; 28: 261-262.
17. Molto A, Mateo L, Lloveras N, Olive A, Minguez S. Visceral leishmaniasis and macrophagic activation syndrome in a patient with rheumatoid arthritis under treatment with adalimumab. Joint Bone Spine 2010; 77: 271-273.
18. Zanger P, Kötter I, Raible A, Gelanew T, Schonian G, Kremsner PG. Successful treatment of cutaneous leishmaniasis caused by Leishmania aethiopica with liposomal amphothericin b in an immunocompromised traveler returning from eritrea. Am J Trop Med Hyg 2011; 84: 692-694.
19. Jeziorski E, Blanchet C, Ludwig C et al. [Pseudotumoral-like recurrence of visceral leishmaniasis in a seven-year-old girl]. Arch Pediatr 2009; 16 (suppl 2): S129-S131.
20. Diza E, Kansouzidou A, Gerou S, Vezyri E, Metallidis S, Antoniadis A. Leishmaniases in northern greece: seroprevalence of the infection and incidence of the disease during the period 2001-2006. Eur J Clin Microbiol Infect Dis 2008; 27: 997-1003.
21. Moral L, Rubio EM, Moya M. A leishmanin skin test survey in the human population of l'alacanti region (Spain): implications for the epidemiology of Leishmania infantum infection in southern Europe. Trans R Soc Trop Med Hyg 2002; 96: 129-132.
22. Federico G, Damiano F, Caldarola G, Fantini C, Fiocchi V, Ortona L. A seroepidemiological survey on Leishmania infantum infection. Eur J Epidemiol 1991; 7: 380-383.
23. Anonymous . Volume 9A of the rules governing medical products in the European Union - guidelines on pharmacovigilance for medicinal products for human use. Brussels: European Union, 2008. Available at: (last accessed 10 June 2011).
24. Spanish registry of adverse events of biological therapies in rheumatic diseases. November 2010 report. Spanish Society of Rheumatology, 2010.
25. Salmon-Ceron D, Tubach F, Lortholary O et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-tnf therapy reported to the 3-year prospective french ratio registry. Ann Rheum Dis 2011; 70: 616-623.
26. L'uso dei farmaci in italia. Rapporto nazionale anno 2006. Rome: Istituto Superiore Di Sanità, 2007.
27. L'uso dei framaci in italia. Rapporto nazionale anno 2007. Rome: Istituto Superiore di Sanità, 2008.
28. L'uso dei framaci in italia. Rapporto nazionale anno 2008. Rome: Istituto Superiore di Sanità, 2009.
29. L'uso dei farmaci in italia. Rapporto nazionale anno 2009. Rome: Istituto Superiore di Sanità, 2010.
30. Glaeske G, Schicktanz C, Janhsen K. Gek-arzneimittel-report 2008. St. Augustin: Asgard-Verlag, 2008.
31. Glaeske G, Schicktanz C. Gek-arzneimittel-report 2010. St. Augustin: Asgard-Verlag, 2010.
32. Sichletidis L, Settas L, Spyratos D, Chloros D, Patakas D. Tuberculosis in patients receiving anti-tnf agents despite chemoprophylaxis. Int J Tuberc Lung Dis. 2006; 10: 1127-1132.
33. Franklin G, Greenspan J, Chen S. Anti-tumor necrosis factor-alpha therapy provokes latent leishmaniasis in a patient with rheumatoid arthritis. Ann Clin Lab Sci 2009; 39: 192-195.
34. Scallon B, Cai A, Solowski N et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002; 301: 418-426.
35. Allenbach C, Launois P, Mueller C, Tacchini-Cottier F. An essential role for transmembrane tnf in the resolution of the inflammatory lesion induced by leishmania major infection. Eur J Immunol 2008; 38: 720-731.
36. Wilhelm P, Ritter U, Labbow S et al. Rapidly fatal leishmaniasis in resistant c57bl/6 mice lacking tnf. J Immunol 2001; 166: 4012-4019.
37. Lohmann-Matthes ML, Luttig B, Hockertz S. Involvement of membrane-associated tnf in the killing of Leishmania donovani parasites by macrophages. Behring Inst Mitt 1991; 88: 125-132.
38. Van den Brande JM, Braat H, van den Brink GR et al. Infliximab but not etanercept induces apoptosis in lamina propria t-lymphocytes from patients with crohn's disease. Gastroenterology 2003; 124: 1774-1785.
39. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-tnf-alpha monoclonal antibody ca2 binds recombinant transmembrane tnf-alpha and activates immune effector functions. Cytokine 1995; 7: 251-259.
40. McLeod C, Bagust A, Boland A et al. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol Assess 2007; 11: 1-158, iii-iv.
41. Hochberg MC, Tracy JK, Hawkins-Holt M, Flores RH. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 2003; 62 (suppl 2): ii13-ii16.
42. Atteno M, Peluso R, Costa L et al. Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. Clin Rheumatol 2010; 29: 399-403.
43. World Health Organization. Leishmaniasis. . Accessed 28, January 2011.